thrombomodulin alfa

DRUG2 trials

Sponsors

Veloxis Pharmaceuticals

Conditions

Chemotherapy-induced Peripheral Neuropathy

Phase 1

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

TerminatedNCT05251727

Veloxis PharmaceuticalsChemotherapy-induced Peripheral Neuropathy

Start: 2022-03-24End: 2024-06-05Updated: 2024-08-19

Phase 2

A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo

WithdrawnNCT04492436

Veloxis PharmaceuticalsChemotherapy-induced Peripheral Neuropathy

Start: 2021-10-31End: 2024-07-31Updated: 2022-02-18

Related Papers

Phase I study of ART-123 in combination with FOLFOX + bevacizumab for patients with metastatic colorectal cancer.

Journal of Clinical Oncology2026-01-10